David R Fogelman

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Emerging drugs for colorectal cancer
    David R Fogelman
    MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
    Expert Opin Emerg Drugs 13:629-42. 2008
  2. pmc Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, UT M D Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 10:368. 2010
  3. doi request reprint Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial
    David Fogelman
    MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:1431-8. 2011
  4. ncbi request reprint Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer
    David R Fogelman
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Anticancer Res 31:1417-20. 2011
  5. doi request reprint Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:2045-53. 2012
  6. doi request reprint The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer
    Mohamed A Khalil
    M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 426, Houston, TX, 77030, USA
    Invest New Drugs 31:1375-83. 2013
  7. doi request reprint Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury
    Julian H Slade
    Department of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Colorectal Cancer 8:225-30. 2009

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Emerging drugs for colorectal cancer
    David R Fogelman
    MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
    Expert Opin Emerg Drugs 13:629-42. 2008
    ..Our understanding of existing drugs, such as oxaliplatin and irinotecan, has become more refined. The incorporation of newer drugs such as bevacizumab and cetuximab has expanded treatment options as well...
  2. pmc Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, UT M D Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 10:368. 2010
    ..The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and results in synergistic antitumor activity with erlotinib in preclinical tumor models...
  3. doi request reprint Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial
    David Fogelman
    MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:1431-8. 2011
    ..The gemcitabine and oxaliplatin (GEMOX) has yielded among the longest progression-free survival durations in patients with advanced pancreatic cancer (APC). We postulated that adding bevacizumab would increase the effectiveness of GEMOX...
  4. ncbi request reprint Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer
    David R Fogelman
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Anticancer Res 31:1417-20. 2011
    ..This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer...
  5. doi request reprint Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:2045-53. 2012
    ..By means of this system, we sought to analyze outcomes of patients with resectable anatomy but heterogeneous biology and physiology who were treated with neoadjuvant therapy...
  6. doi request reprint The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer
    Mohamed A Khalil
    M D Anderson Cancer Center, 1515 Holcombe Blvd Unit 426, Houston, TX, 77030, USA
    Invest New Drugs 31:1375-83. 2013
    ..72). In conclusion, though there was a trend towards improved survival with the addition of erlotinib to gemcitabine and cisplatin, this does not reach statistical significance. ..
  7. doi request reprint Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury
    Julian H Slade
    Department of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Colorectal Cancer 8:225-30. 2009
    ..The literature on hepatic sinusoidal injury after oxaliplatin is reviewed and the proposed pathophysiology is discussed...